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A Single-Institution Experience of 144 Patients
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Michael Liptay, MD,† Sanjib Basu, PhD,† William H. Warren, MD,† Mary Jo Fidler, MD,‡
Marta Batus, MD,‡ Ross A. Abrams, MD,* and Philip Bonomi, MD‡
Background: Concurrent chemoradiotherapy (CRT) is a standard of
care in the treatment of unresectable locally advanced non-small cell
lung cancer (NSCLC). At Rush University Medical Center, patients
with locally advanced NSCLC are treated with split-course CRT in
an attempt to maximize efficacy and tolerability. We reviewed our
experience in advanced NSCLC since 1999. Subset analysis was
performed on poor-risk patients.
Methods: All patients with a diagnosis of stage IIIA/IIIB NSCLC
and treated with definitive split-course CRT between January 1999
and December 2008 were included in this retrospective study. The
primary end point was overall survival. Poor-risk patients were
defined in accordance with ongoing cooperative group trials.
Results: One hundred forty-four patients were identified, 35% stage
IIIA and 65% stage IIIB. There were 52 poor-risk patients and 92
average-risk patients. Median survival for all patients was 20.4
months with an actuarial 32.1% 3-year overall survival rate. Poor-
risk patients demonstrated a median survival of 22.1 months, statis-
tically indistinguishable from the remainder of the cohort (p 
0.21). Acute esophagitis was mild, with a 3% rate of grade 3
esophagitis and no cases of grade 4 or 5.
Conclusions: Split-course CRT appeared effective and was deliv-
ered with a favorable toxicity profile. Poor-risk patients experienced
better than expected survival. Prospective evaluation of split-course
CRT must be completed before it can be considered a standard
treatment option in locally advanced NSCLC.
Key Words: Treatment interruptions, Poor-risk, Locally advanced
NSCLC, Split course chemoradiotherapy, Combined modality
therapy
(J Thorac Oncol. 2011;6: 1079–1086)
Lung cancer is the most common source of cancer mortalityin the United States, responsible for an estimated
160,000 deaths in 2009.1 Non-small cell lung cancer
(NSCLC) accounts for 80% of all lung cancer, and approxi-
mately 40% of patients with NSCLC present with locally
advanced American Joint Committee on Cancer stage IIIA or
IIIB disease.2 Thoracic radiotherapy (RT) alone was the
traditional standard treatment for unresectable NSCLC until
evidence emerged demonstrating a benefit from the addition
of chemotherapy.3–5 Contemporary phase III trials have ex-
amined the sequencing of multimodality treatment and the
value of induction chemotherapy, with evidence suggesting
that concurrent chemotherapy and radiation is superior to a
sequential approach.6–8
Median survivals ranging from 14 to 26 months have
been achieved in relatively good-risk NSCLC patient co-
horts.6–12 Local and distant disease progression remains a
problem afflicting the majority of patients treated with the
accepted standard therapy of 60 to 63 Gy with concurrent
radiosensitizing chemotherapy. Contemporary studies, such
as Radiation Therapy Oncology Group (RTOG) 0617, seek to
intensify treatment via an increased radiation dose, and/or by
delivering more chemotherapy at a systemically active dose,
but the optimal treatment regimen in good-risk patients re-
mains uncertain.
Many patients with locally advanced disease are at
higher risk, presenting with poor pulmonary reserve, poor
performance status (PS), and/or pretreatment weight loss.13
The characteristics of a “poor-risk” patient are difficult to
define with precision. Classical prognostic factors associated
with outcome reported by the RTOG include PS (80 Kar-
nofsky), pretreatment weight loss (8%), age (70 years),
disease stage, hemoglobin level, whether or not chemother-
apy was delivered, and the presence of a positive malignant
effusion.14 Poor-risk patients have not fared well when
treated with concurrent chemoradiotherapy (CRT). A phase II
chemoradiation trial conducted by the Southwest Oncology
Group (SWOG) dedicated to the study of poor-risk patients
reported disappointing results, with median progression-free
survival (PFS) of 6.0 months and median overall survival
(OS) of 10.2 months.13 A Cancer and Leukemia Group B
(CALGB) study in similar patients was more encouraging,
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achieving a PFS and OS of 13.4 and 19.0 months respec-
tively.15 While treatment intensification is clearly needed to
combat high rates of local and distant failure, such efforts are
often hindered by the poor health of the patients. The optimal
regimen for the treatment of poor-risk patients with locally
advanced NSCLC remains an area of active study.
Rush University Medical Center (RUMC) has treated
locally advanced NSCLC patients with a split-course CRT
approach since the early 1980s in an attempt to balance
treatment efficacy with morbidity in this often fragile patient
population. Treatment was delivered based on the hypothesis
that systemic doses of chemotherapy could mitigate the
potential deleterious effects of accelerated repopulation seen
with split-course RT alone. Herein, we review our experience
with split-course CRT since 1999 to assess outcomes in all
patients. Subset analysis was performed to specifically assess
outcomes in poor-risk patients, a common patient type un-
derrepresented in most contemporary chemoradiation trials.
METHODS
Patient Selection
Institutional Review Board approval was obtained for
this retrospective study. Patients with a tissue diagnosis of
NSCLC and clinical stage IIIA or IIIB who received defini-
tive split-course CRT between January 1999 and December
2008 were identified via the RUMC tumor registry and a
radiation oncology departmental database.
Pretreatment Evaluation
Before initiating the treatment, all patients were staged
with chest computed tomography (CT), standard blood work,
and brain imaging. A pathologic diagnosis of NSCLC was
required. Mediastinal sampling and pathologic confirmation
of mediastinal disease was not required for treatment or
inclusion in this retrospective study. Ninety percent of pa-
tients incorporated positron emission tomography (PET) stag-
ing, and bone scans were obtained when PET imaging was
unavailable. Mediastinal lymph nodes were considered
involved if the standardized uptake value was greater than
2.5 or if the lymph nodes measured greater than 1 cm
short-axis diameter. Thirty-five percent of patients had
surgical confirmation of mediastinal disease. Patients were
evaluated and managed via a multidisciplinary clinic with
participating medical oncologists, radiation oncologists,
and thoracic surgeons.
Treatment Regimen
The standard Rush split-course CRT regimen (Figure 1)
consisted of four treatment cycles, each cycle 21 days in
length. RT was delivered once daily, 180 to 200 cGy per
fraction, on days 1 to 5 and 8 to 9 (or 10) to a total dose of
6000 to 6400 cGy. Chemotherapy was delivered in the form
of a systemically dosed platinum doublet. Most patients
received carboplatin (Paraplatin; Bristol-Myers Squibb,
New York City, NY) area under the curve 4 on day 1, with
either paclitaxel (Taxol; Bristol-Myers Squibb) 100 mg/m2
on days 1 and 8 or etoposide (VePesid; Bristol-Myers
Squibb) 80 mg/m2 on days 1 to 3. After the completion of
all treatment, patients underwent a chest CT approximately
4 to 6 weeks after the last fraction of RT to assess
response. Patients then underwent serial imaging with
chest CT every 6 to 12 weeks for the first year and every
3 to 6 months the second year.
Treatment: Radiation Techniques
Radiation technique evolved during the study period.
Patients treated before 2005 received treatment with initial
anterior posterior opposed fields followed by off-cord
obliques, in two to four treatment phases. Most patients
received elective treatment of the mediastinum during this
time. Beginning in 2005, most patients were treated with at
least three fields from the outset of therapy, and all fields
were treated on all days. Treatment was delivered in a
single phase, delivering radiation to only areas involved
with disease on CT and/or PET (no elective nodal irradi-
ation). Motion induced by respiration was assessed by
fluoroscopy before 2006 and more recently by four-dimen-
sional CT. The amount of respiratory motion was used to
determine appropriate treatment margins.
Data Collection
End points included OS, defined as the interval between
pathologic diagnosis and death; PFS, defined as the interval
between diagnosis and evidence of any disease recurrence/
progression; distant metastasis-free survival (DMFS), defined
as the time between diagnosis and evidence of distant metas-
tases; and local regional PFS (LRPFS), defined as time
between diagnosis and local progression. LRPFS was deemed
to have occurred when either the primary lesion or medias-
tinum demonstrated progressive disease on serial chest CT
and/or PET. Distant failure was evidenced by imaging find-
ings consistent with metastatic disease and/or histopathology.
Clinical response was defined by Response Evaluation Cri-
teria in Solid Tumors (RECIST).14 Acute toxicity was as-
sessed via review of RT on-treatment visit notes, medical
oncology follow-up notes, RT completion summaries, and a
review of the electronic medical record to document hema-
tologic toxicity as well as evidence of hospital admissions
during or after RT completion. Acute toxicity was scored in
accordance with the Common Toxicity Criteria for Adverse
FIGURE 1. The split-course approach illustrated. Patients
receive either 7 or 8 days of radiotherapy per 3-week cycle
to a total dose of 60–64 Gy.
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Events version 3.0 (CTCAE v3.0). Late RT-related toxicity
was scored in accordance with the Common Toxicity Criteria
2.0 (CTC 2.0).
Data were deemed right-censored if a given event had
not occurred at the time of last follow-up. The Kaplan-Meier
method was used to estimate survival curves for different
patient subpopulations, and the log-rank test was used to test
for significant differences between survival curves.16 Results
were considered statistically significant if the two-sided p
value was 0.05.
Risk Groups
Patients were identified as poor risk if they fulfilled any
of the following criteria derived from contemporary CALGB
and RTOG studies:
1. PS 2
2. Forced expiratory volume in 1 second 1.2 L
3. Greater than 10% pretreatment cancer related weight
loss
4. Age 80 years or older at diagnosis
All other patients were classified as average risk.
RESULTS
Patients
One hundred fifty-eight patients with stage IIIA or IIIB
disease in the chest were identified as having begun curative
treatment in the RUMC department of radiation oncology
during the study period. Fourteen of these patients were
excluded for the following reasons: 7 were oligometastatic, 6
patients were treated with daily rather than split-course RT,
and 1 patient had received induction chemotherapy. One
hundred forty-four patients met inclusion criteria: 92 were
average risk and 52 were poor risk (Table 1). The most
common reason for classification as poor risk was 10%
cancer-related weight loss (42% of poor risk patients), fol-
lowed by PS of 2 (33%) and poor pulmonary function (29%).
Median follow-up on living patients was 36.4 months and 18
months on all patients.
Treatment Compliance and Clinical Response
An ideal split-course CRT regimen concludes in 70
days. Median treatment duration was tightly clustered around
the median value of 72 days (Table 2). Eighty-nine percent of
patients received 5800 cGy. Chemotherapy delivered was
calculated as a percentage of intended administration (Table
2). Carboplatin and paclitaxel was the most commonly used
regimen. Overall mean carboplatin, paclitaxel, and etoposide
administered were 89%, 91%, and 82% of intended. Clinical
response to treatment was assessed prospectively and retro-
spectively using RECIST criteria via chest CT on average 5
weeks after the final fraction of RT.17 The overall clinical
response rate (partial response  complete response) was
59.1%.
Survival
Median OS for the entire group was 20.4 months and
actuarial 3-year OS was 32.1% (Table 3). There was no
significant difference in OS between average-risk and
poor-risk patients (p  0.21, Figure 2). Poor-risk patients
paradoxically had a small superiority in median survival,
22.1 versus 20.0 months, but this difference does not
appear meaningful, as the curves were virtually superim-
posable out to 20 months. After 20 months, average-risk
patients appeared to have better survival, although the tails
of curves must be interpreted with caution. When assessed
individually, 10% weight loss (p  0.49), poor PS (p 
0.16), and poor respiratory status (p  0.90) were not
significantly prognostic for survival. Patients with poor PS
(n  17) demonstrated the strongest trend toward dimin-
ished survival, with a median survival of 13 months,
versus 21.8 months for all other patients. Patients who had
pathologic confirmation of mediastinal nodal status had
median survival of 25.0 months, versus 20.1 months for
those who were staged clinically; this difference was not
significant (p  0.16) (Figure 3). There was no difference
in OS based on RT treatment technique (data not shown).
TABLE 1. Patient Characteristics
Age (yr)
Median (range) 66 (32–86)
Stage group
IIIA 51 (35.4)
IIIB 93 (64.6)
T stage
X 20 (13.9)
1 15 (10.4)
2 33 (22.9)
3 27 (18.8)
4 49 (34.0)
N stage
0 8 (5.6)
1 4 (2.8)
2 81 (56.3)
3 51 (35.4)
Poor riska 52 (36.1)
10% pretreatment weight loss 22 (15.3)
ECOG PS 2 17 (11.8)
FEV1 1.2 L 15 (10.4)
Age 80 9 (6.3)
Histology
Squamous 50 (34.7)
Adenocarcinoma 61 (42.4)
Poorly differentiated 21 (14.6)
Large cell 4 (2.8)
Other 3 (2.1)
Unavailable 5 (3.5)
Pathologic confirmation of N2 disease
Yes 50 (34.7)
No 94 (65.3)
Values are given as N (%).
a Some patients had more than one poor risk factor.
ECOG PS, Eastern Cooperative Oncology Group performance status; FEV1, forced
expiratory volume in 1 sec.
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Progression-Free Survival, Distant Metastasis-
Free Survival, and Local Regional Progression-
Free Survival
Median PFS was 11 months, and 3-year actuarial PFS
was 19.5% (Table 3). Distant recurrence was involved in 88%
of first failures (66% of all patients), while locoregional
recurrence was a component of treatment failure in 46% of all
first failures (33% of all patients) (Table 4).
Toxicity
Complete toxicity data are shown in Table 5. The rate
of febrile neutropenia was 8%. Grade 3 esophagitis was
FIGURE 2. Overall survival stratified by risk group.
FIGURE 3. Overall survival stratified by mediastinal staging
method.
TABLE 3. Outcomes
All Patients
OS
Median (mo) 20.4
3 yr (%) 32.1
PFS
Median (mo) 11.0
3 yr (%) 19.5
DMFS
Median (mo) 13.6
3 yr (%) 27.0
LRPFS
Median (mo) 29.7
3 yr (%) 48.5
OS, overall survival; PFS, progression-free survival; DMFS, distant metastasis-free
survival; LRPFS, local regional progression-free survival.
TABLE 4. Pattern of Failure
First Failure
Local regional 12 (9)
Distant 54 (41)
Both 35 (27)
None 41 (31)
Values are given as N (%). Percentage taken from 132 patients completing the
treatment.
TABLE 2. RT Treatment Details and Response
Weight change during CRT
Increase 59 (44.7%)
Decreased or unchanged 66 (50.0%)
Unavailable 7 (5.3%)
RT treatment technique
Traditional 51 (38.6%)
Contemporary 81 (61.4%)
RT duration (d)
Median (range) 72 (50–116)
25–75 percentile 70–74
Regimen
Carboplatin and paclitaxel 79 (59.8%)
Carboplatin and etoposide 42 (31.8%)
Other 4 (3.0%)
Unavailable 7 (5.3%)
Median Mean
Chemotherapy percentage delivered (all patients)
Carboplatin 95% 87%
Paclitaxel 95% 88%
Etoposide 75% 82%
Chemotherapy percentage delivered (poor risk)
Carboplatin 95% 85%
Paclitaxel 95% 84%
Etoposide 75% 81%
Radiotherapy delivered (poor risk) 6000 cGy 5670 cGy
RT treatment duration 77 d 27 (20%)
Clinical response
CR 19 (14.4%)
PR 59 (44.7%)
SD 27 (20.5%)
PD 0 (0.0%)
Non-CR 7 (5.3%)
Unavailable 20 (15.2%)
Percentage taken from 132 patients completing the treatment.
CRT, chemoradiotherapy; RT, radiotherapy; CR, complete response; PR, partial
response; SD, stable disease; PD, progressive disease.
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uncommon, with a crude rate of 3%. The crude rate of grade
3/4 pneumonitis was 14.5% for the entire cohort. When
stratified by RT treatment technique, the actuarial risk of
pneumonitis at 12 months was 26.2% with traditional tech-
niques versus 7.1% (p  0.002) with modern RT techniques
(Figure 4). There was a 4% acute and 1% late treatment-
related mortality rate. Treatment-related mortality occurred in
5.6% of poor-risk patients and 3.3% of average-risk patients.
The majority of treatment-related mortality was secondary to
pneumonia.
DISCUSSION
The outcomes resulting from multimodality treatment
of locally advanced NSCLC remain suboptimal, and the most
favorable treatment regimen is unknown. Modern regimens
using concurrent chemoradiation  induction/adjuvant che-
motherapy offer a 15 to 25% chance of long-term survival but
at the potential cost of significant morbidity, such as esoph-
agitis. Our data suggest that split-course CRT may be a
means to decrease acute toxicity while achieving equivalent
or improved survival outcomes to standard regimens in pa-
tients with locally advanced NSCLC.
TABLE 5. Acute and Late Toxicity
Grade 2 Grade 3 Grade 4 Grade 5
CTCAE v3.0 acute toxicity
Neutropenia 9 (6) 16 (11) 13 (9) 0 (0)
Febrile neutropenia 0 (0) 8 (6) 1 (1) 2 (1)
Leukopenia 34 (24) 16 (11) 15 (11) 0 (0)
Anemia 50 (35) 6 (4) 1 (1) 0 (0)
Thrombocytopenia 5 (4) 4 (3) 0 (0) 0 (0)
Fatigue 19 (13) 1 (1) 0 (0) 0 (0)
Pneumonitis 10 (7) 19 (13) 2 (1) 0 (0)
Esophagitis 5 (4) 4 (3) 0 (0) 0 (0)
Infection 0 (0) 11 (8) 4 (3) 3 (2)
Hemoptysis 0 (0) 0 (0) 0 (0) 1 (1)
CTC v2.0 RT-related
late toxicity
Esophageal/GI 3 (2) 0 (0) 0 (0)
Pulmonary 1 (1) 0 (0) 2 (1)
Values are given as N (%).
CTCAE, Common Toxicity Criteria for Acute Events; CTC, Common Toxicity
Criteria; RT, radiotherapy; GI, gastrointestinal.
FIGURE 4. Incidence of pneumonitis stratified by RT treatment technique.
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There are significant clinically supported radiobiologic
concerns associated with the use of split-course RT.18–22 It is
accepted that the introduction of breaks into the RT course
allows accelerated repopulation, resulting in suboptimal out-
come. Studies in multiple tumor sites have demonstrated the
detriment of prolonging treatment time and/or introducing
breaks into RT, leading to an established (and evidence
based) bias against split-course RT.19–22 Still, the strongest
evidence demonstrating the importance of repopulation per-
tains to patients treated with RT alone. The interaction be-
tween RT and concurrent chemotherapy is complex and
incompletely understood. It is possible that administration of
concurrent chemotherapy decreases or eliminates the effects
of repopulation. The question of whether efficacy is compro-
mised by splitting the RT course when combined with con-
current chemotherapy is legitimate and can only be answered
in a prospective study. Our experience suggests that survival
outcomes were not compromised versus conventional CRT
TABLE 6. Contemporary Outcomes with Chemoradiation
Study
IIIA/
IIIB (%) Induction Chemo Concurrent Chemo
Consolidation
Chemo RT
Median
Survival (mo)
3-yr OS
(%)
Hanna et al.11
Arm 1 (n  74) 39/61 None Cisplatin 50 mg/m2 days
1,8/etoposide 50 mg/m2
days 1–5a
None 59.4 Gy/1.8 Gy
once daily
23.2 26
Arm 2 (n  73) 42/58 None Cisplatin 50 mg/m2 days
1,8/etoposide 50 mg/m2
days 1–5a
Docetaxel 59.4 Gy/1.8 Gy
once daily
21.2 27
Vokes et al.10
Arm 1 (n  170) 49/48 Carbo AUC6 and Taxol
200 mg/m2
a
Weekly Carbo AUC2 and
Taxol 50 mg/m2
None 66 Gy/2.0 Gy
once daily
14.0 23
Arm 2 (n  161) 48/46 None Weekly Carbo AUC2 and
Taxol 50 mg/m2
None 66 Gy/2.0 Gy
once daily
12.0 19
Belani et al.7
Arm 1 (n  74) 36/64 Carbo AUC6 and Taxol
200 mg/m2
a
Weekly Carbo AUC2/Taxol
45 mg/m2
None 63 Gy/1.8 Gy
once daily
12.7 15
Arm 2 (n  94) 36/64 None Weekly Carbo AUC2/Taxol
45 mg/m2
Carbo AUC6 and
Taxol 200
mg/m2
a
63 Gy/1.8 Gy
once daily
16.3 17
Arm 3 (n  91) 38/62 Carbo AUC6 and Taxol
200 mg/m2
a
None None 63 Gy/1.8 Gy
once daily
13.0 17
Curran et al.8
Arm 1 (n  610) None Cisplatin 100 mg/m2 days
1,29/vinblastine 5 mg/m2
qwk
None 60 Gy/2.0 Gy
once daily
17.0 21 (4 yr)
Arm 2 (n  610) None Cisplatin 50 mg/m2 days
1,8/etoposide 50 mg/m2
PO twice daily  10 wk
days 1,2,5,6
None 69.6 Gy/1.2 Gy
twice daily
15.2 17 (4 yr)
Arm 3 (n  610) Cisplatin 100 mg/m2
days 1,29/vinblastine
5 mg/m2 qwk
None None 60 Gy/2.0 Gy
once daily
14.6 12 (4 yr)
Furuse et al.6
Arm 1 (n  156) 31/69 None Cisplatin 80 mg/m2 day
1/mitomycin 8 mg/m2
day 1/vindesine 3 mg/m2
days 1,8a
None 56 Gy/2.0 Gy
split
16.5 22.3
Kiura et al.12
Arm 1 (n  101) 33/67 None Cisplatin 80 mg/m2 day
1/mitomycin 8 mg/m2
day 1/vindesine 3 mg/m2
days 1,8a
None 60 Gy/2.0 Gy
once daily
23.7 16.6 (5 yr)
Arm 2 (n  99) None Cisplatin 40 mg/m2 days
1,8/docetaxel 40 mg/m2
days 1,8a
None 60 Gy/2.0 Gy
once daily
26.8 23.5 (5 yr)
Present study
n  144 35/65 None Carbo AUC4 day 1/taxol
100 mg/m2 days 1,8  4
None 60 Gy/2.0 Gy
split
20.4 32
a Two cycles delivered.
Gielda et al. Journal of Thoracic Oncology • Volume 6, Number 6, June 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1084
regimens, bearing in mind the limitations of our retrospective
analysis (Table 6).
Treatment decisions in poor-risk patients with locally
advanced NSCLC are challenging secondary to insufficient
data. Most trials of concurrent chemoradiation for NSCLC
specifically excluded patients with poor PS, 10% weight
loss, or age 80 years or older. Two phase II studies performed
by SWOG were dedicated solely to poor-risk patients.
SWOG S9429 treated 60 patients with carboplatin, etoposide,
and concurrent RT, resulting in a median OS of 13 months.23
SWOG S9712 attempted to build on this experience by
adding three cycles of consolidation paclitaxel, but survival
was not improved (median OS 10.2 months) and toxicity was
increased.13 CALGB 30106 reported the outcomes of 21
poor-risk patients (PS 2 or weight loss 5%) treated with
induction carboplatin and paclitaxel, followed by 6600 cGy
with concurrent and consolidation gefitinib. PFS and OS were
an encouraging 13.4 and 19.0 months, respectively.15 The
enthusiasm accompanying these results was tempered, how-
ever, given the fact that 39 good-risk patients treated in the
same trial with the same regimen (plus radiosensitizing con-
current carboplatin and paclitaxel) achieved markedly infe-
rior outcomes (median OS 13 months).
Daily thoracic RT with concurrent chemotherapy is
physically demanding for all patients but particularly for
poor-risk patients. Treatment-related toxicity can negatively
impact quality of life and increase patient vulnerability to
intercurrent illness.24 At the same time, inability to deliver
effective therapy may increase susceptibility to disease pro-
gression. SWOG S9712 illustrated these issues in the poor-
risk population; at various points in the protocol, 13.8% of
patients discontinued treatment secondary to toxicity, 12.6%
of patients were removed for progressive disease, 8% discon-
tinued from unrelated death/health decline, and only 47% of
patients received CRT and three cycles of consolidation.13
These issues remain significant in average-risk patients as
well, where it is recognized that the delivery of adjuvant
chemotherapy after definitive CRT and the delivery of defin-
itive CRT after induction chemotherapy both result in a
suboptimal percentage of administered treatment.7
One of the advantages of split-course CRT was the
ability to administer a high percentage of intended treatment.
In our study, 90% of patients received 5800 cGy thoracic
RT, and 90% of the intended dose of systemically active
chemotherapy (in patients treated with carboplatin and pac-
litaxel) was delivered. Poor- and average-risk patients re-
ceived a similar high percentage of treatment, potentially
contributing to the identical outcomes between the two
groups. Tolerability was secondary to low rates of acute
toxicity, particularly severe esophagitis, where our rate of 3%
grade 3/4 esophagitis compared favorably with the 7 to 28%
rates encountered in contemporary studies using conventional
daily CRT.7,9,11,13,23 It should be noted, however, that the use
of split-course CRT did not appear to impact the rate of
radiation pneumonitis, which was comparable to the rate
observed with conventional regimens.7 Nevertheless, we hy-
pothesize that minimizing esophagitis improved nutritional
status and overall patient well-being during treatment,
thereby allowing administration of intended treatment and
improving patient resistance to comorbid illness/treatment
toxicity.24
Split-course CRT resulted in an encouraging 20-month
median survival for all patients, with mild toxicity. Poor-risk
patients fared as well as average-risk patients, suggesting that
the tolerability of the split course regimen decreased the
prognostic value of weight loss, PS, age, and pulmonary
function. It should be noted that the poor-risk group had a
slightly higher percentage of stage IIIA patients (42% versus
31%), and poor-risk patients were somewhat less likely to be
staged IIIB secondary to N3 nodal status (31% versus 38%).
A subtle selection bias cannot be ruled out, but a strong bias
with meaningful implications for our results is unlikely, given
the tendency of our institution to offer split-course CRT to
virtually all patients with nonmetastatic disease. Hence, split-
course CRT appears to perform well in poor and average-risk
patients alike with respect to the standard of care. However,
the 36% and 67% rates of locoregional and distant failure
encountered in our study population highlight the need for
improved treatment strategies.
The use of split-course CRT may offer potential bene-
fits going forward. The excellent tolerability observed in our
study suggests that RT dose escalation could be readily
accomplished without compromising the therapeutic index.
RT dose escalation is crucial to combat high rates of local
failure and has shown promise in published reports.25–28
Adaptive treatment has been proposed as a potential means to
decrease toxicity and facilitate dose escalation, but the ability
to decrease RT volumes during a conventional course of CRT
may be limited.29 Split-course treatment allows a greater time
for response, thereby allowing greater volume reductions.
PET/CT-guided adaptive treatment could potentially shrink
fields further still, leading to greater improvement in the
therapeutic index.30
Our study has significant limitations. It is subject to the
biases inherent to all retrospective reports. Particularly ger-
mane to this study are issues surrounding patient inclusion
and evaluation of toxicity. With respect to patient inclusion,
all patients who began curative intent split-course CRT dur-
ing the study interval were included in an attempt to ensure
that patient capture was 100%. With respect to toxicity, it is
possible that minor toxicities may have been underscored, but
major acute toxicity was documented in patient records.
Mediastinal lymph node sampling to confirm disease stage
was not required for inclusion, and this represents another
significant weakness. However, lack of surgical staging of the
mediastinum is not uncommon in a fragile patient cohort; in
SWOG S9429, only 37% of patients had surgical confirma-
tion of mediastinal disease (compared with 35% of patients in
our experience). In our series, patients staged surgically
actually experienced longer survival versus those who were
not, arguing against overstaging, but it remains that our
results may have been influenced by incorrect staging. Also,
with respect to stage migration, the near universal use of PET
staging in our series may have improved our results versus
benchmark CRT trials by excluding patients with occult
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metastatic disease. Despite these limitations, our data suggest
that split-course CRT is effective and highly tolerable.
In conclusion, split-course CRT appeared to achieve
survival outcomes comparable to the standard of care in the
setting of locally advanced NSCLC in both poor- and aver-
age-risk patients. Although these results are retrospective, the
split-course CRT regimen demonstrated a favorable toxicity
profile and resulted in better than expected survival in poor-
risk patients. Split-course CRT remains nonstandard, pending
prospective evaluation, but our results suggest that such
evaluation may be worthwhile. As efforts continue to in-
crease treatment intensity, the use of a split-course construct
could improve the therapeutic index.
REFERENCES
1. American Cancer Society Cancer Statistics 2009. Available at: http://
www.cancer.org/downloads/STT/500809web.pdf. Accessed July 30,
2009.
2. American Joint Committee on Cancer Staging Manual, 6th Ed. Chicago,
Springer Publishing, 2002.
3. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the
patterns of failure in patients with unresectable non-oat cell carcinoma of
the lung treated with definitive radiotherapy. Report by the Radiation
Therapy Oncology Group. Cancer 1987;59:1874–1881.
4. Le Chevalier T, Arriagada R, Tarayre M, et al. Significant effect of
adjuvant chemotherapy on survival in locally advanced non-small-cell
lung carcinoma. J Natl Cancer Inst 1992;84:58.
5. Dillman RO, Seagren SL, Prospert KJ, et al. A randomized trial of
induction chemotherapy plus high-dose radiation versus radiation alone
in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940–
945.
6. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent
versus sequential thoracic radiotherapy in combination with mitomycin,
vindesine, and cisplatin in unresectable stage III non-small-cell lung
cancer. J Clin Oncol 1999;17:2692–2699.
7. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy
regimens of paclitaxel and carboplatin for locally advanced non-small-
cell lung cancer: a randomized phase II locally advanced multi-modality
protocol. J Clin Oncol 2005;23:5883–5891.
8. Curran W, Scott C, Langer C, et al. Phase III comparison of sequential
vs concurrent chemoradiotherapy for patients (pts) with unresected stage
III non-small cell lung cancer (NSCLC): report of Radiation Therapy
Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2003;22:Abstr
2499.
9. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemother-
apy with or without surgical resection for stage III non-small-cell lung
cancer: a phase III randomised controlled trial. Lancet 2009;374:379–
386.
10. Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy
followed by chemoradiotherapy compared with chemoradiotherapy
alone for regionally advanced unresectable stage III non-small-cell lung
cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698–
1704.
11. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin,
etoposide, and concurrent chest radiation with or without consolidation
docetaxel in patients with inoperable stage III non-small-cell lung
cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol
2008;26:5755–5760.
12. Kiura K, Takigawa N, Segawa Y, et al. Randomized phase III trial of
docetaxel and cisplatin combination chemotherapy versus mitomycin,
vindesine, and cisplatin combination chemotherapy with concurrent
thoracic radiation therapy for locally advanced non-small-cell lung
cancer: OLCSG 0007. J Clin Oncol 2008;26:Abstr 7515.
13. Davies AM, Chansky K, Lau DHM, et al. Phase II study of consolidation
paclitaxel after concurrent chemoradiation in poor-risk stage III non-
small-cell lung cancer: SWOG S9712. J Clin Oncol 2006;24:5242–
5246.
14. Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis
of 1999 Radiation Therapy Oncology Group (RTOG) patients with
locally-advanced non-small-cell lung cancer (LA-NSCLC): identifica-
tion of five groups with different survival. Int J Radiat Oncol Biol Phys
2000;48:1475–1482.
15. Ready N, Ja¨nne PA, Bogart J, et al. Chemoradiotherapy and gefitinib in
stage III non-small cell lung cancer with epidermal growth factor
receptor and KRAS mutation analysis: Cancer and Leukemia Group B
(CALGB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol
2010;5:1382–1390.
16. Kaplan E, Meier P. Nonparametric estimation from incomplete obser-
vations. J Am Stat Assoc 1958;53:457–481.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to
evaluate response to treatment in solid tumors. European Organization
for Research and Treatment of Cancer, National Cancer Institute of the
United States, National Cancer Institute of Canada. J Natl Cancer Inst
2000;92:205–216.
18. Hall EJ, Giaccia AJ. Radiobiology for the Radiologist, 6th Ed. Phila-
delphia, PA: Lippincott Williams & Wilkins, 2006.
19. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group
(RTOG) phase III randomized study to compare hyperfractionation and
two variants of accelerated fractionation to standard fractionation radio-
therapy for head and neck squamous carcinomas: first report of RTOG
9003. Int J Radiat Oncol Biol Phys 2000;48:7–16.
20. Saunders MI, Dische S, Barrett A, et al. Continuous, hyperfractionated,
accelerated radiotherapy (CHART) versus conventional radiotherapy in
non-small cell lung cancer: mature data from the randomized multi-
center trial. Radiother Oncol 1999;52:137–148.
21. Petereit DG, Sarkaria JN, Chappell R, et al. The adverse effect of
treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol
Phys 1995;32:1301–1307.
22. Begg AC, Hofland I, Van Glabekke M, et al. Predictive value of
potential doubling time for radiotherapy of head and neck tumor pa-
tients: results from the EORTC cooperative trial 22851. Semin Radiat
Oncol 1992;2:22–25.
23. Lau DH, Crowley JJ, Gandara DR, et al. Southwest Oncology Group
phase II trial of concurrent carboplatin, etoposide, and radiation for
poor-risk stage III non-small-cell lung cancer. J Clin Oncol 1998;16:
3078–3081.
24. Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G, et al. Associa-
tion of nutritional status and serum albumin levels with development of
toxicity in patients with advanced non-small cell lung cancer treated
with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Can-
cer 2010;10:50.
25. Blackstock AW, Socinski MA, Bogart J, et al; Cancer and Leukemia
Group B. Induction plus concurrent chemotherapy with high-dose (74
Gy) 3-dimensional (3-D) thoracic radiotherapy in stage III non-small
cell lung cancer. Preliminary report of Cancer and Leukemia Group B
(CALGB) 30105. Proc Am Soc Clin Oncol 2006;24(18S):Abstr 7042.
26. Lee CB, Socinski A, Lin L, et al. High-dose 3D chemoradiotherapy in
stage III non-small cell lung cancer (NSCLC) at the University of North
Carolina: long-term follow up and late complications. Proc Am Soc Clin
Oncol 2006;24(18S):Abstr 7145.
27. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation im-
proved local tumor control and overall survival in patients withinoperable/
unresectable non-small-cell lung cancer: long-term results of a radiation
dose escalation study. Int J Rad Oncol Biol Phys 2005;63:324–333.
28. Schild S, McGinnis WL, Graham D, et al. Results of a phase I trial of
concurrent chemotherapy and escalating doses of radiation for unresect-
able non-small cell lung cancer. Int J Rad Oncol Biol Phys 2006;65:
1106–1111.
29. Spoelstra FO, Pantarotto JR, van So¨rnsen de Koste JR, et al. Role of
adaptive radiotherapy during concomitant chemoradiotherapy for lung
cancer: analysis of data from a prospective clinical trial. Int J Radiat
Oncol Biol Phys 2009;75:1092–1097.
30. Feng M, Kong FM, Gross M, et al. Using fluorodeoxyglucose positron
emission tomography to assess tumor volume during radiotherapy for
non-small-cell lung cancer and its potential impact on adaptive dose
escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys
2009;73:1228–1234.
Gielda et al. Journal of Thoracic Oncology • Volume 6, Number 6, June 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1086
